Natera, Inc. (NTRA)
| Market Cap | 55.86B +111.1% |
| Revenue (ttm) | 2.71B +37.8% |
| Net Income | -192.35M |
| EPS | -1.37 |
| Shares Out | 144.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,184,770 |
| Open | 418.41 |
| Previous Close | 414.30 |
| Day's Range | 385.47 - 418.41 |
| 52-Week Range | 181.00 - 437.41 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 416.39 (+7.44%) |
| Earnings Date | Nov 5, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $416.39, which is an increase of 7.44% from the latest price.
News
Natera to Report its Third Quarter Results on November 5, 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September...
Natera highlights Signatera Genome Assay at ESMO Congress
Natera (NTRA) provided a summary of key findings from the European Society for Medical Oncology Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s t...
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Onc...
Natera price target raised to $430 from $320 at BTIG
BTIG raised the firm’s price target on Natera (NTRA) to $430 from $320 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Natera announces new data presented at ASN Kidney Week 2026
Natera (NTRA) announced new data that was recently presented at the American Society of Nephrology, ASN, Kidney Week 2026, highlighting the value genetic testing can provide for patients with CKD.
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Ne...
Natera initiated with a Buy at Roth Capital
Roth Capital last night initiated coverage of Natera (NTRA) with a Buy rating and $475 price target The company offers an “unmatched catalyst runway” in oncology diagnostics, the analyst tells…
Natera initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Natera (NTRA) with a Buy rating and $475 price target
Natera price target raised to $500 from $375 at Canaccord
Canaccord raised the firm’s price target on Natera (NTRA) to $500 from $375 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results…
Natera presents 20 abstracts at ESMO 2026
Natera (NTRA) announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology, ESMO, Annual Congress, taking place October 23-26 in Madrid, Spa...
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at th...
Natera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms
Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been ...
Natera price target raised to $460 from $360 at JPMorgan
JPMorgan raised the firm’s price target on Natera (NTRA) to $460 from $360 and keeps an Overweight rating on the shares. The firm updated models in the life science tools…
Natera price target raised to $480 from $340 at TD Cowen
TD Cowen raised the firm’s price target on Natera (NTRA) to $480 from $340 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics space…
Natera, Transcode to collaborate on Phase 2a trial of TTX-MC138
Natera (NTRA) and TransCode Therapeutics (RNAZ) announced a strategic collaboration in colorectal cancer, CRC. The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-M...
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage compan...
Natera price target raised to $435 from $355 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Natera (NTRA) to $435 from $355 and keeps an Overweight rating on the shares.
Natera announces MCED assay granted BDD by U.S. FDA
Natera (NTRA) announced that its multi-cancer early detection, MCED, assay has been granted Breakthrough Device designation, BDD, by the U.S. Food and Drug Administration, FDA. The BDD is designed for...
FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been grante...
Natera enrolls first patients in new Signatera-guided trial
Natera (NTRA) announced the enrollment of the first patients in a new Signatera-guided trial in melanoma, sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for…
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided tri...
Natera price target raised to $475 from $340 at Barclays
Barclays raised the firm’s price target on Natera (NTRA) to $475 from $340 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
Natera announces new data shared at ASTRO 2026 on Signatera
Natera (NTRA) announced new data recently shared at the American Society for Radiation Oncology, ASTRO, 2026 Annual Meeting. The presentations marked Natera’s first participation at ASTRO and a signif...
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Onc...